Articles and Publications

Pharmaceutical products must go through research, clinical trials, and  registration with the health ministry or other  authorised government bodies, before going to the public. This multi-tiered composite procedure gave birth to extending  the term of patents directed to pharmaceutical  products up to 25 years in many jurisdictions. Circumstances surrounding such cases may present difficulties to the patent owner.

In Russia, we sometimes see information in the foreign media that intellectual property (IP) in Russia has died, and no protection or enforcement of IP rights is possible. Aside from newspaper articles occasionally appearing in the media, we may see that allegation is repeated in the 14th package of restrictive measures issued by the Council Regulation (EU) or in the 2024 Special 301 Report issued by the Office of the United States Representative. One may wonder where that information comes from.

Following the current political situation and the sanctions imposed on Russia, some Western companies decided to re-consider their trading and other business activities in Russia. Taking advantage of the moment, some market players, acting in bad faith, are attempting to register famous brands or their imitations in their own name without the consent of the real owners of those brands.

IP owners express concerns regarding their IP in Russia in the wake of publications in the media. Aside from individual writers misleading information was also published by respectable organizations. Specifically, the European Council issued 14th package of restrictive measures against Russia and answered questions in connection with those measures.

In a general case, a user who seeks a compulsory license must convince the court that their dependent invention is an important technical achievement and has considerable economic advantages.